Risk adjusted net present value: What is the current valuation of Incyte’s Epacadostat?

Epacadostat is a small molecule commercialized by Incyte, with a leading Phase II program in Salivary Gland Cancer.

Related Posts

ESC 2024: Amvuttra data signals positive prospects in c...

Aug 31, 2024

Causaly secures $60 Million in series B funding

Jul 15, 2023

Abortion policy in the spotlight, DeSantis’ importation...

Aug 25, 2023